IsoPlexis Corp: management transactions · United States · SEC (Form 4)

About IsoPlexis Corp

IsoPlexis Corp was a U.S.-based life sciences tools and healthcare technology company that had been listed on the Nasdaq market in the United States under the ticker ISO before its 2023 combination with Berkeley Lights. The company was incorporated in Delaware in March 2013 and operated from Branford, Connecticut, where it built its R&D, manufacturing and commercial capabilities. Its business was centered on functional single-cell proteomics: the ability to detect highly informative biological signals from small cell subsets in order to better understand disease biology and support the development of more precise therapies. From a product and revenue-model standpoint, IsoPlexis sold integrated systems, software and consumables to research laboratories working in immunology, oncology, cell and gene therapy, infectious disease, inflammatory disorders and neurological disease. Its core platforms included IsoCode and CodePlex, and later Duomic, a product designed to bridge proteomics with sequencing-based workflows. These offerings were aimed at revealing functional activity inside individual cells, complementing standard genomic or transcriptomic tools. That focus gave IsoPlexis a differentiated position in a specialized, high-science segment of the market, where the value proposition was not broad scale but deep biological insight. Competitively, IsoPlexis operated in a market dominated by much larger life-science instrument and reagents companies, including Thermo Fisher Scientific, Bio-Rad Laboratories and Becton, Dickinson, which were identified in SEC materials as competitors across certain product categories. IsoPlexis’ strength was its niche expertise and its focus on “functional biology” for complex diseases. The company also stated in SEC filings that its products had been adopted by researchers around the world, including leading global pharmaceutical companies and a significant share of major U.S. cancer centers, supporting its scientific credibility and market traction. A major recent development was the merger announced in December 2022 and completed in March 2023 with Berkeley Lights. Following closing, the combined company was renamed PhenomeX, and IsoPlexis ceased to trade as an independent listed company. For investors, that transaction is the defining recent event: it reflected both the strategic value of IsoPlexis’ single-cell proteomics platform and the need for scale in a capital-intensive tools market. In practical terms, IsoPlexis represented an innovative but specialized U.S. Nasdaq-listed healthcare tools business whose technology was ultimately folded into a broader functional cell biology platform.